Antonia Martinez-Conde

Medicine · Health Sciences

3h-index95citations17works1.12yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(5), Ovarian cancer diagnosis and treatment(3), RNA modifications and cancer(3), DNA Repair Mechanisms(2), Cancer Genomics and Diagnostics(2)

Publications17 total

The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)
Cell Death Discovery·2025· 2 citedOpen Access
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance
Frontiers in Oncology·2024· 7 citedOpen Access
Abstract 7135: Preclinical effects of Tumor Treating Fields (TTFields) with PARP inhibitors in ovarian cancer
Cancer Research·2024
Abstract 7219: Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin for treatment of cervical cancer
Cancer Research·2024
Abstract 7134: Treatment of pancreatic cancer cells with tumor treating fields (TTFields) and PARP inhibitors
Cancer Research·2024
Abstract B071: Tumor Treating Fields (TTFields) together with PARP inhibitors for treatment of pancreatic cancer cells
Cancer Research·2024
Abstract B027: Preclinical efficacy of Tumor Treating Fields (TTFields) applied with PARP inhibitors or carboplatin in ovarian cancer
Cancer Research·2024
Abstract B028: Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer
Cancer Research·2024
Abstract 2723: Treatment of gastric cancer cells with tumor treating fields (TTFields) and concomitant FOLFOX
Cancer Research·2023· 2 cited
Abstract 4883: Pan cancer transcriptomic response to tumor treating fields (TTFields)
Cancer Research·2023
Abstract 2666: Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin or paclitaxel for treatment of cervical cancer
Cancer Research·2023
Abstract 6182: Tumor treating fields (TTFields) concomitant with PARP inhibitors or carboplatin for treatment of ovarian cancer cell lines
Cancer Research·2023· 1 cited
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959
Cancers·2023· 1 citedOpen Access
Efficacy of combining tumor treating fields (TTFields) with a PARP inhibitor in ovarian cell lines (300.5)
Gynecologic Oncology·2022· 1 cited
Abstract 2601: Concomitant treatment of ovarian cell lines with Tumor Treating Fields (TTFields) and PARP inhibitors
Cancer Research·2022· 1 cited
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
Cancers·2022· 33 citedOpen Access
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models
Lung Cancer·2021· 47 cited

Frequent Co-authors

Eyal Dor-On(17), Adi Haber(17), Moshe Giladi(17), Yoram Palti(17), Uri Weinberg(13), Roni Frechtel-Gerzi(12), Einav Zeevi(7), Hila Ene(6), Shiri Davidi(5), Hila Fishman(5), Yelena Mumblat(4), Yaara Porat(4), Tali Voloshin(4), Kerem Ben‐Meir(4), Roni Monin(4), Itai Tzchori(4), Daria Gerasimova(4), Ori Braten(3), Anna Shteingauz(3), Catherine Tempel-Brami(3)